Dave Levitan

Researchers conducted the QUADRA trial to examine if niraparib could improve outcomes in heavily pretreated patients with ovarian cancer.

The combination of trastuzumab and paclitaxel 'represents an important step forward in de-escalating therapy' for HER2+ breast cancer.

Telerehabilitation and pharmacological pain management approaches were tested in patients with advanced cancers, including prostate cancer, to see if pain and function could be improved.

Researchers tested the addition of adjuvant chemotherapy to androgen suppression and radiotherapy in patients with localized high-risk prostate cancer.

A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL.

Researchers tested whether the use of alternative control probes to classify HER2 status in breast cancer could lead to substantial false positives.

Researchers tested the PI3K inhibitor umbralisib in patients with relapsed/refractory marginal zone lymphoma in a phase II study that was presented at the AACR Annual Meeting.

A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

A pooled analysis of two trials presented at the AACR Annual Meeting looked at the use of pembrolizumab in patients with heavily pretreated extensive small-cell lung cancer.

Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting.

Researchers looked at the role of biomarkers associated with systemic inflammation among patients with triple-negative breast cancer.

In this study, researchers aimed to further characterize differences in hospice use in a cohort of ovarian cancer patients.

A randomized trial tested whether lymphadenectomy would improve survival outcomes in patients with advanced ovarian cancer.

A large Danish registry study looked at the effects of post-diagnosis use of low-dose aspirin on prostate cancer mortality.

Researchers tested the combination of docetaxel and ADT in a phase III randomized trial of patients with high-risk nonmetastatic prostate cancer.

A trial showed that tumor mutational burden may be effective as a biomarker in patients treated with immunotherapy.

The US Food and Drug Administration has approved the subcutaneous administration of trastuzumab for patients with HER2-overexpressing breast cancer.

Researchers studied the combination of a cellular vaccine known as HS-110 and nivolumab in an early-phase trial of patients with advanced non–small-cell lung cancer.

An early-phase trial tested the combination of pembrolizumab with trastuzumab in patients with PD-L1–positive, trastuzumab-resistant, advanced HER2+ breast cancer.

Researchers conducted a validation study of four breast cancer risk models currently in use.

The addition of denosumab to adjuvant aromatase inhibitor therapy offered improved outcomes in women with postmenopausal HR+ early breast cancer.

Researchers investigated the risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer.

A score derived from CT imaging using a machine learning radiomics approach was able to reliably identify epithelial ovarian cancer patients with poor survival outcomes.

Researchers tested whether conservative management of adnexal masses classified as benign could lead to subsequent malignant ovarian cancer.

A set of simple interventions succeeded in reducing disparities in lung cancer care between black and white patients across five cancer centers.

The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of < 50%.

The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.

The large precision medicine trial known as Lung-MAP has announced it will expand to patients with all non–small-cell lung cancers, accounting for as many as 85% of all lung cancer diagnoses in the US.

Researchers compared hypofractionated radiotherapy vs a conventional regimen to study outcomes and toxicity in breast cancer patients.

Researchers conducted a study to evaluate the short-term clinical outcomes of varying approaches to immediate implant-based breast reconstruction in the UK.